ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Cost-effectiveness analysis (CEA) of ovarian cancer preventive strategies for women with BRCA1/2 pathogenic variants: the role of surveillance.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management of cancer risk for BRCA pathogenic variants (PV) carriers varies depending on countries, with different strategies. However, some strategies lack of cost-effectiveness evidence. This study fills this gap assessing the cost-effectiveness of a combined ovarian cancer (OC) surveillance and prevention strategy in BRCA1/2 PV carriers.
methodsThe developed Markov decision model simulated the progression of breast cancer and OC in BRCA1/2 PV carriers separately. The model estimated benefits and costs associated with three OC surveillance strategies: Surveillance-Surgery (SS), annual surveillance until salpingo-oophorectomy (SO) and radical mastectomy (RM) at appropriate age; Only-Surgery (OS), without surveillance, and No preventive Intervention (NI). Extensive literature review informed the model. The analysis adopted the Italian NHS perspective and a lifetime horizon, with direct healthcare costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio as outcome measures. Base-case, deterministic and probabilistic sensitivity analyses were performed.
findingsIn BRCA1 PV carriers, SS yielded lifetime cost savings of €8 382 and €2 008 compared to NI and OS, respectively, while also gaining 2.65 and 0.45 QALYs per patient. Similar trends were observed for BRCA2 PV carriers. Sensitivity analyses confirmed SS as the dominant strategy across all scenarios, with a > 80% probability of being most cost-effective at a willingness-to-pay threshold of €20 000 per QALY gained.
interpretationCombined OC surveillance and prevention strategy for BRCA1/2 PV carriers at appropriate age represents a highly cost-effective approach compared to surgical prophylaxis alone or no intervention. Periodical counselling in a multidisciplinary team affects high surgical acceptance rates, that are crucial for maximizing the effectiveness of such programs.
Indexed as
Identifiers
41862743What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.